Image for Gradientech’s QuickMIC® showed rapid and reliable results in new study

Gradientech’s QuickMIC® showed rapid and reliable results in new study

Gradientech is pleased to announce positive study results obtained from clinical blood culture samples using QuickMIC, Gradientech’s ultra-rapid antibiotic susceptibility testing (AST) system. The antibiotic susceptibility results were available in an average of 3 hours, which is considerably faster than any other phenotypic AST method in the market.

The study was run in collaboration with Uppsala University Hospital. A total of 41 clinical samples from sepsis patients were analysed using the QuickMIC system. Results for gram-negative bacteria were obtained in an average of 3 hours and had an overall categorical agreement of 94.9% as compared to routine diagnostics. Obtaining fast results is of essence to provide appropriate antibiotic treatment and increase sepsis survival.  
“These results confirm the value of our QuickMIC system for providing reliable results ultra-rapidly” said Sara Thorslund, CEO at Gradientech. “We are very happy with these promising results and looking forward to continue our collaboration with Uppsala University Hospital and other partners around these time-critical samples”.  

For further information, please contact:
Sara Thorslund, PhD, CEO Gradientech
Tel: +46 736 29 35 80

Gradientech is an ISO13485 certified company since 2017


Gradientech AB
Uppsala Science Park
SE-751 83 Uppsala

About Gradientech

Gradientech develops, manufactures and sells innovative microfluidic products for high-quality analysis of the behavior of cells and organisms in response to gradients of biomolecules. Our aim is to pioneer life science and healthcare.

Copyright © 2023 Gradientech. All rights reserved. Gradientech, QuickMIC and CellDirector are registered trademarks or trademarks of Gradientech AB.

Next-generation antimicrobial susceptibility testing

Take a look at our E-book